Pfizer Inc. research snapshot
PFE AI stock analysis reads Pfizer Inc. as a broad biopharma franchise rebuilding growth after the COVID-19 revenue reset, with a recovering share price and a busy late-July 2026 catalyst calendar. At the August 2, 2026 data cutoff, PFE closed near $25.01 on July 31, 2026 with an implied market capitalization of about $142.54 billion. The stock trades at a low forward earnings multiple near 8.8x and a 6.88% dividend yield, and recent news includes positive Phase 3 LITFULO vitiligo results, FDA priority review for a prostate cancer combination, and FDA approval of PADCEV plus Keytruda in bladder cancer. The risk case still centers on patent losses, COVID product decline, high debt from the Seagen deal, dividend coverage pressure, and an upcoming Q2 2026 earnings report on August 4, 2026. This page is informational research, not investment advice.
Current price
$25.01
Market cap
$142.54 billion
AI score
59 / 100
Rating
Recovering large-cap pharma with high yield, cheap forward valuation, and pipeline catalysts offset by patent and debt risks
Trend status
Mixed technical trend near the 50-day average but below the 200-day
Data cutoff (updated monthly)
August 4, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | Pfizer sells prescription medicines, vaccines, oncology therapies, and specialty products across global regulated markets, with revenue now less dependent on pandemic products than in 2021 and 2022. | High |
| Moat | The moat comes from patents, clinical data, regulatory approvals, manufacturing scale, payer access, physician trust, and global commercial reach, but it weakens when exclusivity expires. | Medium-high |
| Management | Chairman and CEO Albert Bourla is steering a rebuild around oncology, obesity, cost savings, capital discipline, and business development, with recent FDA wins and positive Phase 3 reads supporting the strategy. | Medium |
| Financial trend | TTM revenue through March 2026 was $63.315 billion, up 1.36% year over year, with FY2025 revenue of $62.579 billion, down 1.7%, and Q2 2026 results scheduled for August 4, 2026. | High |
| Valuation | At $25.01, PFE traded near 19.1x TTM GAAP EPS, 8.76x forward EPS, 15.0x TTM free cash flow, 1.58x book value, 2.25x sales, and a 6.88% dividend yield. | Medium-high |
| Technical trend | The stock recovered from the 52-week low near $23.11 and sits around its 50-day moving average near $25.08, but remains below the 200-day moving average near $25.83. | Medium |
| Risk level | The biggest risks are patent expirations, weak COVID product demand, regulatory pricing pressure, trial failure, integration risk, high debt, and dividend sustainability. | Medium-high |
| AI confidence | High for descriptive research, arithmetic checks, and consensus data. Lower for exact stock outcomes because PFE can reprice quickly around the August 4 earnings print, trial data, FDA decisions, patent news, guidance, rates, and dividend expectations. | High data confidence |
| Investment certainty | Medium-low certainty. Pfizer has scale, cash flow, and a cheap forward multiple, but a buy decision depends on whether new products and cost actions can offset patent and COVID product pressure. | Medium-low |
PFE AI stock forecast
The PFE AI stock forecast uses scenario math around the $25.01 July 31, 2026 close and the midpoint of 2026 adjusted EPS guidance near $2.90 as a normalized earnings base. The audited three-year framework produced a bearish area near $21.2, a base area near $30.8, and a bullish area near $41.4 before dividends, broadly consistent with the analyst low of $24, average of $28.75, and high of $35.46 over a shorter horizon.
$38 to $42
More likely if oncology assets like PADCEV and TALZENNA scale, obesity and vitiligo programs advance, COVID product declines stabilize, debt falls, the dividend stays covered, and investors revalue PFE from the low single-digit earnings multiple toward a low-teens multiple.
$29 to $32
More likely if adjusted EPS grows at a low-single-digit pace, patent pressure is manageable, cost savings hold, and the market applies about a 10x multiple to normalized earnings near the midpoint of 2026 guidance.
$20 to $23
More likely if the August 4 earnings print disappoints, pipeline assets underdeliver, Eliquis or other patent losses pressure revenue faster than launches scale, COVID sales keep falling, leverage limits flexibility, or the dividend is questioned.
PFE AI technical analysis
PFE AI technical analysis was mixed as of the August 2, 2026 cutoff. PFE closed at $25.01 on July 31, 2026, essentially at its 50-day moving average near $25.08 to $25.09, and still below the 200-day moving average near $25.83. RSI near 52 was neutral, ADX near 17.6 indicated a weak trend, and the stock had recovered about 8% from its 52-week low near $23.11.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $25.01 | StockAnalysis closing quote for July 31, 2026, used for market cap and valuation math at the August 2, 2026 cutoff. |
| Near support | $24.55 to $24.91 | July 30 and July 31 intraday and closing lows clustered around $24.55 to $24.91, with the 52-week low at $23.11 and a June low near $23.62. |
| Near resistance | $25.50 to $26.49 | The July 28 high near $25.50 and mid-June highs near $26.21 to $26.49 form the first resistance band above the 200-day average. |
| 50-day moving average | About $25.08 to $25.09 | StockAnalysis and Barchart both placed the 50-day average near $25.08 to $25.09, with the price trading right at that level. |
| 200-day moving average | About $25.83 | StockAnalysis and Barchart both placed the 200-day average near $25.83, which caps the recovery until price closes above it with volume. |
| Momentum | RSI about 52 | StockAnalysis and Barchart both reported RSI near 52, neutral rather than overbought or oversold, with a slightly positive directional tilt. |
| Volume | Elevated large-cap liquidity | Recent daily volume ran around 27 to 49 million shares, with volume spikes on earnings-related and news-driven days. |
| Volatility | Moderate but catalyst-driven | Barchart reported 14-day historic volatility near 19.5% and an average true range near $0.51, with the August 4 earnings report a near-term volatility trigger. |
| Invalidation | Close below $24.55, then $23.11 | A break below recent support weakens the mean-reversion and recovery case. A failed move back above $25.83 keeps the trend-following setup unconfirmed. |
PFE AI trading strategy
The PFE AI trading strategy is a rules-based research framework for a large-cap pharma stock with high dividend yield, a recovering but still below-trend price, and material pipeline, patent-cycle, and earnings catalysts. It is not personal advice and should be paired with live quotes, filings, event calendars, and position sizing rules.
Watch for PFE to reclaim the $25.83 200-day moving average and then hold above the $25.50 to $26.49 band with volume support before treating the trend as repaired.
A close back below the 50-day average near $25.08, or a break below $24.55, should invalidate the short-term setup.
If PFE pulls back toward the $24.55 to $24.91 area without new pipeline, patent, dividend, pricing, or guidance damage, compare the selloff with free cash flow, leverage reduction, and normalized EPS guidance.
Do not rely on dividend yield alone. A high yield can reflect market concern about growth, balance sheet repair, or dividend coverage, and the August 4 earnings report can reset the setup.
Track the August 4, 2026 Q2 report and full-year guidance, oncology growth, obesity and LITFULO milestones, Eliquis and Ibrance patent exposure, COVID product decline, Seagen integration, cost savings, debt, cash flow, and dividend coverage.
Reduce confidence if growth depends mainly on valuation rerating while product revenue, pipeline milestones, or balance sheet metrics fail to improve.
Investment research summary
Pfizer converts scientific research, clinical evidence, patents, regulatory approvals, manufacturing capability, and global physician and payer access into revenue from medicines and vaccines.
Pfizer has scale, regulatory know-how, global distribution, patents, and clinical data depth. The moat is real but product-specific, and it narrows when exclusivity expires or better therapies emerge.
The thesis fails if patent losses and COVID declines outpace new launches, obesity and vitiligo assets disappoint, Seagen integration under-earns, debt limits capital allocation, or pricing pressure reduces returns.
Albert Bourla has emphasized oncology, obesity, cost discipline, business development, and eventual balance sheet deleveraging. Recent FDA approvals and positive Phase 3 data support the rebuild, but execution quality will be judged by pipeline conversion and cash returns.
Biopharma benefits from aging demographics, oncology innovation, vaccines, obesity treatment, and chronic disease demand, but the industry faces patent cliffs, payer pressure, litigation, tariffs on imported drugs, and binary clinical outcomes.
PFE trades at a low forward earnings multiple, low sales multiple, and high dividend yield versus many healthcare peers, but the margin of safety depends on whether normalized earnings near management guidance are durable after patent and COVID product pressure.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| PFE price | $25.01 at the July 31, 2026 close | StockAnalysis quote snapshot | August 2, 2026 |
| Market capitalization | $142.54 billion, verified as $25.01 x 5.70 billion shares | financial_rigor.py market cap verification | August 2, 2026 |
| Shares outstanding | 5.70 billion | StockAnalysis statistics | August 2, 2026 |
| TTM revenue | $63.315 billion through March 2026, up 1.36% year over year | StockAnalysis financials | August 2, 2026 |
| FY2025 revenue | $62.579 billion, down 1.65% from FY2024 | StockAnalysis financials and Pfizer 2025 Form 10-K | August 2, 2026 |
| TTM net income | $7.490 billion, with TTM EPS of $1.31 | StockAnalysis statistics and financials | August 2, 2026 |
| TTM free cash flow | $9.483 billion, with FY2025 free cash flow of $9.075 billion | StockAnalysis cash flow statement | August 2, 2026 |
| Q1 2026 cash and short-term investments | $13.075 billion as of March 29, 2026 | StockAnalysis balance sheet | August 2, 2026 |
| Q1 2026 total debt | $64.455 billion as of March 29, 2026 | StockAnalysis balance sheet | August 2, 2026 |
| 2026 guidance | $59.5 billion to $62.5 billion revenue and $2.80 to $3.00 adjusted diluted EPS, reaffirmed with Q1 2026 results | Pfizer Q1 2026 earnings release | August 2, 2026 |
| Analyst consensus | Buy rating with an average price target of $28.75, a low of $24, and a high of $35.46 | S&P Global analyst consensus via StockAnalysis forecast | August 2, 2026 |
| Valuation checks | 19.08x TTM GAAP EPS, 8.76x forward EPS, 15.03x free cash flow, 1.58x book value, 2.25x sales, and 6.88% dividend yield | financial_rigor.py valuation verification | August 2, 2026 |
| Technical indicators | 50-day moving average near $25.08, 200-day moving average near $25.83, and RSI near 52 | StockAnalysis statistics and Barchart technical analysis | August 2, 2026 |
This PFE AI stock analysis is an informational research tool only. It is not investment advice, a recommendation to buy or sell Pfizer Inc., or a guarantee of future returns. Forecast scenarios are based on available public data as of August 2, 2026 and can be wrong if fundamentals, valuation, patent timing, clinical data, regulation, capital allocation, market conditions, or the August 4, 2026 earnings report differ from expectations.
Design trading strategies visually with 10+ indicators. Set entry/exit conditions and risk management, then generate Pine Script code with no coding required.
Filter and discover stocks based on market cap, dividend yield, P/E ratio, sector, and more. Screen thousands of stocks with real-time data.
Smart AI-driven stock selection with fundamental screening, analyst estimates, and key metrics. Filter by P/E, market cap, dividends, and more.
